| Previous Close | 0.0350 |
| Open | 0.0400 |
| Bid | 0.04 x 0 |
| Ask | 0.04 x 0 |
| Day's Range | 0.0350 - 0.0400 |
| 52 Week Range | 0.0200 - 0.1000 |
| Volume | 746,800 |
| Avg. Volume | 681,314 |
| Market Cap | 13.937M |
| Beta (3Y Monthly) | 6.52 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.01 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.27 |
Focus Graphite Inc. (TSX VENTURE:FMS) ("Focus" or the "Company") announces the closing of the first tranche of a non-brokered private placement (the "Offering") for gross proceeds of $650,000. The Company has issued 13,000,000 units (the "Units") at a price of $0.05 per Unit. Each Unit is comprised of one (1) flow-through common share and one common share purchase warrant (a "Warrant").
FSE: FKC) (“Focus” or the “Company”) is pleased to announce that its superfine, high-performance, conductive graphite used in the production of Lithium-Ion batteries is currently being tested by Major Battery Companies. Additionally, some battery technologies require that the graphite in use be almost 100% pure. Sources of pure, high-grade graphite are scarce and not readily available in consistent supply.
FSE: FKC) (“Focus” or the “Company”) is excited by the successful results of its efforts to advance the production of superfine, high-performance graphite using its proprietary processing technology. Already a source of high-grade graphite, suitable for use across a wide range of technology applications from energy storage to biomedicine, Focus Graphite is excited by the opportunity to expand its range of high-grade graphite. Over the last 4 years, Focus Graphite has embarked on an intensive value added product development and testing program.
FSE: FKC) (“Focus” or the “Company”) introduces its roadmap for refining BioMedical Grade Graphite to supply Grafoid’s product line of BioMedical Applications. Already an established source of high grade graphite, suitable for use in BioMedicine, Focus Graphite is also excited by the potential of its Rare Earth projects –such as the Kwyjibo Rare Earth Element (“REE”) Project (“Kwyjibo”) – which increases the range of materials that Focus may have the ability supply in the future. Within biomedicine, powerful imaging techniques from the single molecule to the whole organism directly impact the fundamental science or diagnosis.
FSE: FKC) has agreed to expand upon certain disclosures (“Disclosures”) made in their June 28, 2018 News Release (“News Release”) which announced the results of the Preliminary Economic Assessment (“PEA”) for the Kwyjibo Rare Earth Element (“REE”) Project “(Kwyjibo”), located in Québec, a Marketing Agreement formalizing an existing contractual relationship announced in a March 13, 2018 news release (“Marketing Agreement”) and Addendums (“Addendums”) to Offtake Agreements press released and filed on SEDAR on October 5, 2015 (“Offtake Agreements”).